Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

Table 3 Drug survival at one, two, and three years by diagnosis

	Drug survival [95% confidence interval]
Diagnosis	One year	Two years	Three years
Rheumatoid arthritis	0.83 [0.81–0.84]	0.72 [0.71–0.74]	0.65 [0.63–0.67]
All spondylarthritis	0.88 [0.86–0.90]*	0.82 [0.79–0.84]*	0.74 [0.71–0.78]*
Ankylosing spondylitis	0.88 [0.85–0.91]	0.82 [0.78–0.86]	0.76 [0.70–0.80]
Psoriatic arthritis	0.88 [0.84–0.90]	0.81 [0.77–0.84]	0.73 [0.67–0.78]
Undifferentiated spondylarthritis	0.88 [0.81–0.91]	0.83 [0.76–0.88]	0.72 [0.60–0.80]
Crohn's related spondylarthritis	0.90 [0.79–0.95]	0.86 [0.73–0.93]	0.82 [0.69–0.91]
Other spondylarthritis	0.79 [0.53–0.92]	0.61 [0.31–0.81]	0.61 [0.31–0.81]

*p of the difference versus survival at the same time in rheumatoid arthritis < 0.001 (by log-rank test).

ISSN: 1478-6362